Key result
Cardioplexol™ demonstrated non-inferiority to Buckberg solution for myocardial protection, yielding similar peak troponin-T levels while reducing the time to complete cardiac arrest.
Why the study?
Effective cardioplegic cardiac arrest is crucial for myocardial protection and preserving postoperative contractile function, prompting evaluation of the efficacy and safety of the new Cardioplexol solution.
Does Cardioplexol compared to Buckberg solution provide non-inferior myocardial protection in patients undergoing elective cardiac surgery?
RCT (n=248)
Single-blind
1:1 ratio via web-based central unrestricted randomization
No
Does Cardioplexol compared to Buckberg solution provide non-inferior myocardial protection in patients undergoing elective cardiac surgery?
Cardioplexol is non-inferior to Buckberg solution for myocardial protection during cardiac surgery, while offering faster cardiac arrest and shorter cross-clamp times.
Answers are grounded in this paper and cite their sources.
Cardioplexol™ meets non-inferiority for safety and efficacy versus Buckberg; supports its adoption as an alternative cardioplegic solution.
Objectives Effective and reliable cardioplegic cardiac arrest is crucial for maximizing myocardial protection and preserving postoperative contractile function. Aim of this study was to demonstrate, in line with an ongoing European registration procedure, the efficacy and safety of the new Cardioplexol™ solution. Methods Single-centre, single-blind, randomized, active-controlled phase-3 non-inferiority trial comparing Cardioplexol™ and Buckberg solutions during cardiac surgery. Patients planed for elective CABG, valve surgery and/or aortic root surgery, were considered eligible after meeting all inclusion and exclusion criteria. Peak troponin-T (TnT) during the first 24 h post-reperfusion was defined as primary endpoint. Intraoperative and ICU-related secondary endpoints were also evaluated, as were safety endpoints. Results Out of 248 operated patients, 226 (100 Cardioplexol™, 126 Buckberg) were considered for per-protocol analysis. Peak-TnT was similar in both groups (0.77 vs. 0.78 ng/ml) and non-inferiority of Cardioplexol™ was confirmed. Delay before complete cardiac arrest (11 vs. 71 s, p < 0.001) and cross-clamp time (51.2 vs. 60.7 min, p < 0.001) were shorter after Cardioplexol™. The defibrillation rate was also significantly reduced (10% vs. 52%, p < 0.001). Although not statistically significant, cumulative dose of catecholamines within 24 h postreperfusion (6,202 vs. 7,170 µg/kg, p = 0.07), and ICU stay (38.1 vs. 44.0 h, p = 0.110) also appeared reduced after Cardioplexol™. Mortality was lower after Cardioplexol™ (1 pt. vs. 5 pts.). Safety parameters were comparable in both groups. Conclusion Efficacy and safety of Cardioplexol™ were demonstrated. Clinical Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-004198-10/results , Eudra CT-No: 2011-004198-10.
No takes yet. Share an insight, caveat, or question.
Stahel et al. (2025) conducted an RCT in Cardiac surgery requiring cardiopulmonary bypass (n=248). Cardioplexol™ vs. Buckberg blood cardioplegia was evaluated on Peak troponin-T (TnT) during the first 24 h post-reperfusion (Ratio 0.99, 95% CI 0.84-1.16). Cardioplexol™ demonstrated non-inferiority to Buckberg solution for myocardial protection, yielding similar peak troponin-T levels while reducing the time to complete cardiac arrest.
Synapse has enriched 10 related papers. Consider them for comparative context: